Martin W. Mackay's most recent trade in Charles River Laboratories International Inc. was a trade of 2,076 Stock Options (Right to Buy) done . Disclosure was reported to the exchange on May 21, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Charles River Laboratories... | Martin W. Mackay | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2025 | 2,076 | 2,076 | - | - | Stock Options (Right to Buy) | |
| Charles River Laboratories... | Martin W. Mackay | Director | Grant, award, or other acquisition of securities at price $ 134.98 per share. | 21 May 2025 | 946 | 13,477 (0%) | 0% | 135.0 | 127,691 | Common Stock |
| Charles River Laboratories... | Martin W. Mackay | Director | Grant, award, or other acquisition of securities at price $ 134.98 per share. | 21 May 2025 | 815 | 14,292 (0%) | 0% | 135.0 | 110,009 | Common Stock |
| SpringWorks Therapeutics Inc | Martin W. Mackay | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2025 | 10,060 | 20,023 (0%) | 0% | 0 | Common Stock | |
| Rallybio Corp | Martin W. Mackay | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2025 | 28,500 | 28,500 | - | - | Option (Right to Buy) | |
| Rallybio Corp | Martin W. Mackay | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 92,857 | 92,857 | - | - | Option (Right to Buy) | |
| SpringWorks Therapeutics Inc | Martin W. Mackay | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jul 2024 | 29,445 | 29,445 | - | - | Stock Option (Right to Buy) | |
| SpringWorks Therapeutics Inc | Martin W. Mackay | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jul 2024 | 9,963 | 9,963 (0%) | 0% | 0 | Common Stock | |
| Charles River Laboratories... | Martin W. Mackay | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2024 | 1,311 | 1,311 | - | - | Stock Options (Right to Buy) | |
| Charles River Laboratories... | Martin W. Mackay | Director | Grant, award, or other acquisition of securities at price $ 228.41 per share. | 13 May 2024 | 559 | 12,159 (0%) | 0% | 228.4 | 127,681 | Common Stock |
| Charles River Laboratories... | Martin W. Mackay | Director | Grant, award, or other acquisition of securities at price $ 228.41 per share. | 13 May 2024 | 372 | 12,531 (0%) | 0% | 228.4 | 84,969 | Common Stock |
| Rallybio Corp | Mackay W. Martin | Director, Executive Chairman | 15 Feb 2024 | 216,000 | 216,000 | - | - | Option (Right to Buy) | ||
| Charles River Laboratories... | Martin W. Mackay | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jul 2023 | 95 | 11,600 (0%) | 0% | 0 | Common Stock | |
| Charles River Laboratories... | Martin W. Mackay | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2023 | 338 | 11,505 (0%) | 0% | 0 | Common Stock | |
| Charles River Laboratories... | Martin W. Mackay | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2023 | 1,669 | 1,669 | - | - | Stock Options (Right to Buy) | |
| Charles River Laboratories... | Martin W. Mackay | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2023 | 664 | 11,167 (0%) | 0% | 0 | Common Stock | |
| Rallybio Corp | Martin W. Mackay | Director, Chief Executive Officer | 06 Feb 2023 | 214,000 | 214,000 | - | - | Option (Right to Buy) | ||
| Charles River Laboratories... | Martin W. Mackay | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2022 | 1,512 | 1,512 | - | - | Stock Options (Right to Buy) | |
| Charles River Laboratories... | Martin W. Mackay | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2022 | 549 | 10,211 (0%) | 0% | 0 | Common Stock | |
| Charles River Laboratories... | Martin W. Mackay | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2022 | 292 | 10,503 (0%) | 0% | 0 | Common Stock | |
| Rallybio Corp | Martin W. Mackay | Director, Chief Executive Officer | 07 Feb 2022 | 62,000 | 62,000 | - | - | Option (Right to Buy) | ||
| Charles River Laboratories... | Martin W. Mackay | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 63 | 9,662 (0%) | 0% | 0 | Common Stock | |
| Charles River Laboratories... | Martin W. Mackay | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2021 | 1,151 | 1,151 | - | - | Stock Options (Right to Buy) | |
| Charles River Laboratories... | Martin W. Mackay | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2021 | 355 | 9,380 (0%) | 0% | 0 | Common Stock | |
| Charles River Laboratories... | Martin W. Mackay | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2021 | 219 | 9,599 (0%) | 0% | 0 | Common Stock |